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Abstract
Background: Differential expression analysis of (individual) genes is often used to study their roles in diseases.
However, diseases such as cancer are a result of the combined effect of multiple genes. Gene products such
as proteins seldom act in isolation, but instead constitute stable multi-protein complexes performing dedicated
functions. Therefore, complexes aggregate the effect of individual genes (proteins) and can be used to gain
a better understanding of cancer mechanisms. Here, we observe that complexes show considerable changes in
their expression, in turn directed by the concerted action of transcription factors (TFs), across cancer conditions.
We seek to gain novel insights into cancer mechanisms through a systematic analysis of complexes and their
transcriptional regulation.
Results: We integrated large-scale protein-interaction (PPI) and gene-expression datasets to identify complexes
that exhibit significant changes in their expression across different conditions in cancer. We devised a log-linear
model to relate these changes to the differential regulation of complexes by TFs. The application of our model
on two case studies involving pancreatic and familial breast tumour conditions revealed: (i) complexes in core
cellular processes, especially those responsible for maintaining genome stability and cell proliferation (e.g. DNA
damage repair and cell cycle) show considerable changes in expression; (ii) these changes include decrease and
countering increase for different sets of complexes indicative of compensatory mechanisms coming into play in
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tumours; and (iii) TFs work in cooperative and counteractive ways to regulate these mechanisms. Such aberrant
complexes and their regulating TFs play vital roles in the initiation and progression of cancer.
Conclusions: Complexes in core cellular processes display considerable decreases and countering increases in
expression, strongly reflective of compensatory mechanisms in cancer. These changes are directed by the concerted
action of cooperative and counteractive TFs. Our study highlights the roles of these complexes and TFs and
presents several case studies of compensatory processes, thus providing novel insights into cancer mechanisms.
Availability: http://www.bioinformatics.org.au/tools-data – CONTOURv2
Background
Transcriptional regulation is a fundamental mechanism by which all cellular systems mediate the activation or
repression of genes, thereby setting up striking patterns of gene expression across diverse cellular conditions
– e.g. across cell-cycle phases [1–3], normal vs cancer states [3] or stress conditions [4]. Such regulation
of gene expression is executed by the concerted action of transcription factors (TFs) that bind to specific
regulatory DNA sequences associated with target genes [5, 6]. Deciphering the roles of TFs is a significant
challenge and has been the focus of numerous studies, with great interest being recently shown in cancer [3,
4,7–9]. For example, Bar-Joseph et al. [3] identified periodically expressed cell-cycle genes in human foreskin
fibroblasts to understand their differential regulation between normal and cancer conditions. Nebert [7]
surveyed TF activities in cancer, emphasizing the roles of TFs as proto-oncogenes (gain-of-function) that
serve as accelerators to activate the cell cycle, and as tumour suppressors (loss-of-function) that serve as
brakes to slow the growth of cancer cells. Darnell [8] classified TFs having cancerous or oncogenic potential
into three main kinds – steroid receptors (e.g. oestrogen receptors in breast cancer and androgen receptors in
prostate cancer), resident nuclear proteins activated by serine kinase cascades (e.g. JUN and FOS), and latent
cytoplasmic factors normally activated by receptor-ligand interaction at the cell surface (e.g. STATs and
NFκB). Darnell [8] also discussed the signalling pathways of these TFs (including Wnt-β-catenin, Notch and
Hedgehog signalling) as potential drug targets in cancer. Karamouzis and Papavassiliou [9] discussed rewiring
of transcriptional regulatory networks in breast tumours focusing on subnetworks of estrogen receptor (ERs)
and epidermal growth factor receptor (EGFRs) family members.
Most studies focus on transcriptional regulation of individual target genes. However, diseases such
as cancer are a result of the combined effect of multiple genes. Gene products such as proteins seldom
act in isolation, but instead physically interact to constitute complexes that perform specialized functions.
Studying protein complexes therefore provides an aggregative or “systems level” view of gene function and
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regulation than studying individual proteins (genes). Here we integrate large-scale protein-interaction (PPI)
and gene-expression datasets to examine the differential regulation of complexes across cancer conditions.
An initial analysis
We compiled a list of protein complexes by clustering a network of human PPIs. Co-functional (interact-
ing) proteins are encoded by genes showing high mRNA co-expression [12, 13]. Therefore, we quantified
the “functional activity” for each of these complexes by aggregating pairwise co-expression values between
their constituent proteins. Analysis for two pancreatic-tissue conditions viz normal and ductal adenocar-
cinoma (PDAC) tumour revealed significant changes in co-expression for these complexes between the two
conditions. For example (Figure 1), CHUK-ERC1-IKBKB-IKBKG showed a change in co-expression, inter-
estingly coinciding with changes in its transcriptional regulation by the NFκB-family of TFs. This complex
constitutes the serine/threonine kinase family, while the TFs play essential roles in NFκB signalling pathway
(www.genecards.org) [14], which are implicated in PDAC [15,16].
Based on these observations, here we seek to understand differential co-expression of complexes and its
relationship with differential regulation by TFs between cancer conditions. Therefore we:
• devise a computational model to identify complexes showing significant differential co-expression and
the TFs regulating these complexes; and
• apply the model on two case studies – normal vs PDAC tumour and BRCA1 vs BRCA2 familial breast
tumour conditions – to decipher their roles in these tumours.
In summary (see Methods for details) we compute co-expression values for each of the complexes under
different cancer conditions. We then introduce a log-linear model to relate changes in co-expression of
complexes to changes in their regulation by TFs between these conditions. We apply the model to identify
influential TFs and complexes and validate their roles in cancer.
Results
Experimental datasets
PPI data: We gathered Homo sapiens PPIs identified from multiple low- and high-throughput experiments
deposited in Biogrid (v3.1.93) [23] and HPRD (2009 update) [24]. To minimize false positives in these PPI
datasets, we employed as scoring scheme Iterative-CD [64] (with 40 iterations) to assign a reliability score
(between 0 and 1) to every interaction, and then discarded all low-scoring interactions (< 0.20) to build a
dense high-quality PPI network of 29600 interactions among 5824 proteins (average node degree 10.16).
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Gene expression data: We have performed one of the largest gene expression profiling of familial breast
tumours (n = 74) and stratified them based on BRCA mutation status as BRCA1-, BRCA2- and non-
BRCA1/2 tumours [21]. Among these, BRCA1 and BRCA2 tumours are phenotypically most different [22]
and we consider these two for our analysis here; our dataset contains 19 BRCA1 and 30 BRCA2 expression
samples (GEO accession GSE19177). In addition, we also gathered expression samples from pancreatic
tumours – normal and PDAC matched (39 in each) – from the Badea et al. study [25] (GSE15471).
Sporadic breast tumours constitute 93-95% of all breast tumours and most studies classify these into the
four molecular subtypes, luminal-A, luminal-B, basal-like and HER2-enriched [18–20]. Broadly, basal-like
tumours do not express the ER, PR and HER2 receptors, and exhibit high aggressiveness and poor survival
attributed to distant metastasis, compared to luminal tumours. However, much less is known about familial
tumours (the remaining 5-7%), although studies [20–22] have noted that BRCA1 tumours are predominantly
basal-like while BRCA2 tumours are more hetergeneous and may be HER2-enriched or luminal-like.
Pancreatic tumours, on the other hand, are more uniform with PDAC accounting for most (95%) pan-
creatic tumours and is predominantly characterized by dysfunctioning (by mutation) of the KRAS oncogene
and of the CDKN2A, SMAD4 and TP53 tumour-suppressor genes [16].
Transcription factors: We gathered 1391 TFs from Vaquerizas et al. [26], manually curated from a combined
assessment of DNA-binding capabilities, evolutionary conservation and integration of multiple sources.
Benchmark complexes: For independent validation, we used manually curated human complexes from CO-
RUM [27], a total of 1843 complexes of which we used 722 having size at least 4.
Benchmark genes and TFs in cancer: For validation we used known (mutation-driver) genes (total 118)
from COSMIC [28] and known TFs (total 82) in cancer from [29].
Analysis of PPI networks highlights considerable rewiring between tumour conditions
By integrating PPI and gene expression datasets (see Methods) we obtained two pairs of conditional PPI
networks – normal-PDAC for pancreatic and BRCA1-BRCA2 for breast tumours. Figure 2 shows the
co-expression-wise distribution for protein pairs in these networks. Normal vs PDAC displayed striking
differences in these distributions (KS test: DNP = 23.11 > Kα=0.05 = 1.36), reflecting considerable rewiring
of PPIs. PDAC showed significant loss in co-expression for both positively co-expressed as well as nega-
tively co-expressed interactions compared to normal, indicative of both disruption as well as emergence of
interactions in the tumour. Such rewiring has also been noted in earlier studies [30, 31].
Strikingly enough BRCA1 vs BRCA2 tumours also showed significant differences in PPI distributions
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(Figure 2) (KS test: DB12 = 22.85 > Kα=0.05 = 1.36), reflecting considerable differences in PPI wiring
between the two breast tumours. BRCA1 tumours displayed higher co-expression compared to BRCA2
tumours, ∼15700 PPIs with higher correlations.
DAVID-based [32] functional analysis of these rewired interactions (∆ ≥ 0.50) showed significant (p ≤
0.001) enrichment for the Biological Process (BP) terms – Cell cycle, Chromatin organisation, DNA repair
and RNA splicing, indicating considerable rewiring in core cellular processes responsible for genome stability.
Among these were interactions involving the tumour suppressors TP53 and SMAD4 in PDAC, which are
known genes mutated in the tumour, and the DNA double-strand break (DSB) repair proteins BRE and
BRCC3 along with BRCA1, BRCA2 and TP53, in breast tumours.
Analysis of complexes highlights disruption to core cellular mechanisms in tumours
Matching of complexes using tJ = 0.67 and δ = 0.10 (Methods) resulted in a total of 256 and 277 matched
complexes (M) for normal-PDAC and BRCA1-BRCA2 conditions, respectively (Table 1). The co-expression-
wise distributions (Figure 3) revealed significant differences for both normal vs PDAC as well as BRCA1 vs
BRCA2 conditions (KS test: DNP = 1.69 > Kα=0.05 = 1.36 in pancreatic andDB12 = 5.48 > Kα=0.05 = 1.36
in breast), indicating that rewiring in PPI networks had considerable impact on these complexes. Overall,
we noticed considerable drop in co-expression for PDAC vis-a-vis normal, whereas BRCA1 tumours showed
higher co-expression vis-a-vis BRCA2 tumours (Figures 3 and 4). These differences were larger towards
the higher co-expression ranges which correspond better to active complexes (Figure 3), indicating that
cellular functions were considerably impacted in these tumours. These observations were reproducible using
an independent set of complexes from CORUM (Figures 3 and 4) and were significantly (p < 0.001) greater
than expected by random (using 500 random complexes generated 1000 times).
DAVID-based analysis for complexes displaying changes ≥ 0.4 indicated significant (p < 0.001) enrich-
ment for core cellular pathways involved in genome stability including Cell cycle and DNA repair (Table 2).
The complexes in PDAC were enriched for TGF-β, Wnt and NFκB signalling, all of which are implicated in
pancreatic cancer [16, 36–38]. The complexes in breast tumours reflected aberration in Homologous recom-
bination (HR), a key DSB-repair pathway which includes the breast cancer susceptibility genes BRCA1 and
BRCA2.
Analysis of complexes reveal compensatory mechanisms activated in tumours
We next divided the set of matched complexes M into two subsets:
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• M′ – those with higher co-expression in normal vis-a-vis PDAC, or higher co-expression in BRCA1
tumours vis-a-vis BRCA2 tumours; and
• M′′ – those with lower co-expression in normal vis-a-vis PDAC, or lower co-expression in BRCA1
tumours vis-a-vis BRCA2 tumours.
Table 3 shows changes in co-expression (∆C) observed for M′ and M′′. While most complexes showed
a decrease in co-expression from normal to PDAC (159 out of 256) and from BRCA1 to BRCA2 tumours
(225 out of 277), interestingly a considerable number of complexes showed an increase (96 and 52). But,
the decrease was steeper compared to the increase (max: 0.969 vs 0.421 and 0.761 vs 0.543; avg: 0.336 vs
0.192 and 0.281 vs 0.197). Similar trends were observed using CORUM complexes and were significantly
(p < 0.001) greater than expected by random. We suspect these observations are indicative of compensatory
mechanisms coming into play in these tumours, as explained below.
In the classical work on “hallmarks of cancer”, Hanahan and Weinberg [33] describe seven to ten key
distinguishing hallmarks of tumour cells, among which are limitless replicative potential and self-sufficiency
in growth signals. Cellular mechanisms including cell cycle and DDR are considerably weakened in tumour
cells, but these cells survive on last-standing mechanisms (weak links) to continue proliferation. This is
due to the activation of compensatory or back-up mechanisms. Although these compensatory mechanisms
cannot completely substitute for the weakened or disrupted ones, these are sufficient to enhance the survival of
tumour cells [33,34]. Our analysis reflect such compensatory trends – a fraction of complexes showed increase
in co-expression, but the increase was not as steep as the decrease for the remaining faction. However, a
straightforward Gene Ontology analysis is too general to delineate the roles of the two factions because both
originate from the same or similar processes. We therefore investigated a few specific cases (below).
Examples of compensatory mechanisms and validation for roles in cancer
Normal vs PDAC tumour (Figure 5a): DSB-repair functionality is severely impacted in PDAC [43, 44], with
inactivating mutations in RAD50 and NBS1 attributed to loss of DSB-repair functionality increasing the
risk of pancreatic cancer [43]. DSBs are detected by the MRE11-RAD50-NBS1 (MRN) and Ku70/Ku80
(XRCC6/XRCC5) complexes in the HR and non-homologous end-joining (NHEJ) pathways, respectively. In
HR, the repair process involves recruitment of the BRCA1-A complex (BRCA1-BARD1-FAM175A-UIMC1-
BRE-BRCC3-MERIT40) to sites of DSBs. We observed a decrease in co-expression for all the three com-
plexes, indicating considerable weakening of the DSB machinery. On the other hand, we noticed an increase
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in co-expression for the single-strand break (SSB) and mismatch (MMR) repair complexes XRCC1-POLB-
PNKP-LIG3 and MSH6-MLH1-MLH2-PSM2-PCNA, respectively. The XRCC1 complex is responsible for
SSB repair through sister chromatid exchange following DNA damage by ionizing radiation, while the MSH6
complex is involved in the recognition and repair of mispairs. Together these observations suggest the acti-
vation of SSB and MMR machinery compensating for the loss in DSB-repair machinery; such a functional
relationship has been observed previously between DSB and SSB repair pathways [35].
The NFκB signalling pathway has been strongly implicated in KRAS signalling and pancreatic tumori-
genesis [39, 40]. Consistent with this, we noticed considerable changes in co-expression for several NFκB
complexes including the NFκB1/REL family, which plays important roles in programmed cell death and
proliferation control and is critical in tumour initiation and progression [40]. The calcium-binding proteins
S100A2, S100A8 and S100A9 are known to modulate P53 activity [41] and their over-expression has been
associated with metastatic phenotype of pancreatic cancer [36]. The inactivation of the RAS-associated
RASSF1A and RASSF5 complexes, which act as tumour suppressors [42, 45], is frequent in pancreatic
cancer [42]. The complex DDX20-GEMIN4-PPP4C-PPP4R2 associated with the SMN (survival of motor
neuron), and SNAP23-STX4-VAMP3-VAMP8 associated with vesicular transport, docking and/or fusion of
synaptic vesicles with the presynaptic membrane (www.genecards.org) [14], support tumorigenic invasion of
neural cells in pancreatic cancer [38].
BRCA1 vs BRCA2 tumours (Figure 5b): We observed a lower co-expression for the MMR complex MLH1-
MSH6-MSH2-PMS2-PCNA in BRCA1 tumours compared to BRCA2 tumours; we think this is due to the
parallel roles of BRCA1. BRCA1 has a key role in DSB repair, and BRCA1-deficient cells have defects in
the two DSB repair pathways HR and NHEJ [46]. BRCA1 associates with PCNA and the mismatch repair
proteins MSH2, MSH6 and MLH1 to form the BASC complex, a genome-surveillance complex required to
sense and repair DNA damages [47], thereby also playing a role in the MMR pathway. On the other hand,
BRCA2 has been associated with functions only in HR [49–52]. Therefore, we suspect that although MMR
pathway is compensatorily activated in response to DSB-repair deficiency, BRCA1 tumours exhibit a weaker
MMR pathway compared to BRCA2 tumours because of the direct involvement of BRCA1 in the MMR
pathway.
The DSS1 complex consisting of BRCA2, DSS1 and the integrator subunits mediates the 3’-end processing
of small nuclear RNAs [48], and BRCA2 deficiency could result in a reduced stability of this complex. The
expression of replication factor C complex (RFC2, RFC3 and RFC4) is indicative of proliferative potential
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(high cell division rates) of BRCA1 tumours. We noticed over-expression of this complex in BRCA1 compared
to BRCA2 tumours.
Finally, a considerable number of cancer genes from COSMIC Classic were represented in complexes
showing changes ∆C ≥ 0.10 (Figure 6), suggesting that differential co-expression of complexes is a strong
indicator of tumorigenic processes.
Relating changes in co-expression complexes to their transcriptional regulation
We computed Pearson and Spearman rank coefficients between changes in co-expression of complexes
and their transcriptional regulation as follows. For each complex-pair {Ss, Tt} ∈ M(S, T ), we mea-
sured its change in correlation ∆C(Ss, Tt), and the total change in its regulation by TFs Ff ,
∑
∆R =
∑k
f=1∆R((Ss, Tt), Ff ) (see Methods). This resulted in 226 complex-TF pairs in pancreatic and 241 in
breast with non-zero ∆C and ∆R. Note that we lose at most 13% of complexes (pancreatic: 256 down to
226, breast: 277 down to 241) as a result of our requirement that TFs interact with at least one complexed
protein (Methods). We observed positive Pearson and Spearman coefficients which were supported by CO-
RUM complexes (Table 4). The Spearman coefficients were higher than Pearson in both cases, indicating a
non-linear relationship; this supports our use of a log-linear model (Methods).
Analysing influential TFs in pancreatic and breast tumours
Table 5 lists the TFs with non-zero overall influence identified using our model (see Methods). Extrapolat-
ing from the simplified example (see Methods), the + and − signs can be interpreted as cooperative and
counteractive action of TFs in regulating complexes. As these are overall influence values (that is, across
all complexes and TFs), it is difficult to interpret this straightaway. Therefore, we restrict our focus to only
STAT1 and STAT3. These two TFs are directly involved in pancreatic tumorigenesis and proliferation, and
are thought to play opposite roles – while STAT1 promotes apoptosis, STAT3 is essential for the prolifer-
ation and survival of tumour cells [53]. Solving Equation 5 for STAT1 and STAT3 using only the subset
of complexes they share (#90), we obtained γ(STAT1) = 1.714 and γ(STAT3) = −1.582, i.e. these are
counteractive TFs (Methods). Their shared complexes were enriched for Cell cycle, Apoptosis and RAS
signalling, consistent with the counteractive roles for STAT1 and STAT3 [53].
Differential expression analysis using limma [54] for normal vs PDAC indicated that most of the influential
TFs were significantly up- or down-regulated (Table 5). But, a few influential TFs did not show such
differential expression, for example heat shock factor-1 (HSF1). Investigation into the complexes regulated
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by HSF1 revealed considerable changes in co-expression for the cysteine-aspartic acid protease (caspase)
family including CASP10-CASP8-FADD-FAS (from 1.28 to −0.019), documented in CORUM [27] under
the functional category ‘40.10.02: Apoptosis’. Caspases are involved in signal transduction pathways of
apoptosis, necrosis and inflammation (www.genecards.org) [14], and the role of HSF1 in regulating caspases
thereby contributing to the pathogenesis of pancreatic cancer has been investigated [55].
In the case of BRCA1 vs BRCA2 tumours, only four of the influential TFs (GATA3, ESR1, FOXA1 and
XBP1) were identified as differentially expressed. These four TFs are ER targets. BRCA1 tumours being
predominantly basal-like, do not express ER and therefore show lower expression of ER targets compared to
BRCA2 tumours, which are predominantly luminal-like and express ER [22]. Additionally, Joshi et al. [56],
using a pathway-based analysis, have noted over-representation of ESR1, GATA3, MYC, XBP1, FOXA1
and MSX2 in luminal tumours, and NFκB1, C/EBPβ, FOXO3, JUN, POU2F3 and FOXO1 in basal-like
tumours. We also found higher expression of the NFκB-signalling TFs in BRCA1 tumours – the complex
NFκB1-NFκB2-REL-RELA-RELB composed entirely of NFκB TFs, showed a higher correlation in BRCA1
tumours than BRCA2 tumours. This is consistent with earlier findings [56, 57] that ER-negative tumours
(BRCA1 tumours) display aberrant expression of NFκB which makes these tumours highly aggressive.
These observations also suggest that differential expression is not sensitive enough to identify all the
genes (here, TFs) involved in tumours. Many of the TFs may not be differentially expressed themselves,
but are differentially co-expressed with their target genes. One such possible situation occurs when the TFs
themselves are not mutated or (epigenetically) silenced, but their target genes are.
Finally, 12 of 37 TFs in pancreatic, and 14 of 40 TFs in breast tumours were among the 82 cancer TFs
listed in [29]. DAVID-based functional analysis of TFs showed significant enrichment for several pathways
in cancer (p <1.1E-05, 23.1% genes), in particular the JAK-STAT pathway (p <1.9E-02, 10.3% genes), a
known driver pathway in cancer [53].
Discussion
We had observed considerable PPI rewiring via differential co-expression analysis (Figure 2). In Figure 7, we
now show the PPI network for normal vs PDAC with interactions weighted by the differential co-expression
values. Figure 7a highlights the largest component (558 proteins and 519 interactions), which shows an overall
decrease in co-expression. A considerable number of genes in this component are targets of ubiquitination
(UBC) and sumoylation (SUMO1 and SUMO2) (Figure 7b) possibly causing their inactivation. However,
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there are several pockets showing increase in co-expression. Interestingly some of the genes topologically
central to these pockets are known drug targets in PDAC (Figure 7c), e.g. PLK1 [58] and ANAX2 [59].
Similarly PELP1 which interacts directly with STAT3 and is responsible for cell proliferation and survival
in several tumours [53], is likewise an identified drug target in PDAC [60]. A similar analysis in BRCA1 vs
BRCA2 tumours highlighted increase in PPI co-expression around the mitotic regulators CDK1, CDC20 and
CKS1B and the histone deacetylases HDAC1 and HDAC6; these are known drug targets for which inhibitors
have been developed [61, 62].
We clustered this normal vs PDAC network using MCL (inflation 2.3) both with and without the weights
as input, and we observed that most clusters predominantly constitute only one kind of interactions, either
those showing increase or decrease in co-expression – of the 30 clusters of sizes ≥ 4, 17 had at least two-third
interactions showing decrease, 9 had at least two-third interactions showing increase. Among these, PLK1
belonged to a cluster in which all interactions showed an increase (Figure 7d). Similarly, in the BRCA1 vs
BRCA2 network, CDK1 and CKS1B belonged to a cluster that showed an increase for all its interactions.
These observations suggest that identifying clusters (complexes) that show increase in co-expression could
identify new therapeutic targets in cancer.
Conclusion
Proteins seldom act in isolation, but instead interact to constitute specialized complexes driving key pro-
cesses. We integrated PPI and gene-expression datasets to perform a large-scale unbaised evaluation of
complexes in PDAC and familial breast tumours. These complexes showed considerable changes in expres-
sion, in particular decreases and countering increases, reflecting compensatory processes coming into play in
the tumours. These complexes enable us to explain the possible underlying mechanisms, which is otherwise
difficult only by analysing individual genes. These complexes are driven by the concerted action of influen-
tial TFs, which themselves work in cooperative and counteractive ways. Network-based analysis shows that
complexes could have therapeutic potential in cancer.
Methods
The workflow for our computational approach is depicted in Figure 8, building on our earlier work [63].
From earlier work [63] (upper portion of Figure 8): We first assemble a high-confidence network of hu-
man PPIs to identify human protein complexes. These PPIs are largely devoid of contextual (conditional)
information, and therefore we overlay mRNA expression data of the coding genes, assigning a confidence
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score to each protein pair under normal and tumour conditions. These scores reflect the presence or ab-
sence of interactions under these conditions. Complexes are extracted from these conditional PPI networks
by network clustering; for a detailed background on PPI networks and the complex-extraction procedure,
see [64–67].
In this work (lower portion of Figure 8): The contribution of this work is to relate changes in co-expression
of complexes to changes in their transcriptional regulation by TFs between cancer conditions by introducing
a log-linear model. This enables us to identify influential TFs and to validate their roles in cancer. This
procedure is described in the following subsections.
Measuring changes in co-expression of complexes between conditions
Let H = (V,E) be the human PPI network, where V is the set of proteins and E is the set of interactions
among these proteins, and S = {S1, S2, .., Sn} and T = {T1, T2, ..., Tm} be the sets of protein complexes
extracted from H under any two conditions, say normal and tumour. For each complex Ss ∈ S, we calculate
its co-expression as
C(Ss) =
∑
p,q∈Ss
ρ(p, q)(
|Ss|
2
) , (1)
where ρ(p, q) is the Pearson correlation for the protein pair (p, q). The ρ-values are Fisher-transformed, given
by z = 12 ln(
1+ρ
1−ρ ), which emphasizes the extreme ρ-values; for example, if ρ = +/-0.10 then z = +/-0.043,
but if ρ = +/-0.99 then z = +/-1.149. The co-expression values for T are calculated similarly.
To identify complexes that have changed co-expression between the conditions, we construct the set
M(S, T ) of matching complex pairs such that every pair (Ss, Tt) ∈ M(S, T ) satisfies (a) a differential
co-expression ∆C(Ss, Tt) > 0, and (b) a minimum Jaccard similarity in protein composition J(Ss, Tt) =
|Ss∩Tt|
|Ss∪Tt|
≥ tJ , where
∆C(Ss, Tt) = |C(Ss)− C(Tt)| ≥ δ > 0. (2)
We expect complexes disrupted between the two conditions to have changed their co-expression (including
complete dissolution or new formation) or have gained or lost a few proteins (rewiring within complexes)
and therefore we use a δ > 0 and a high tJ .
Relating changes in co-expression to changes in transcriptional regulation
Let F = {F1, F2, ..., Fk} be the set of TFs. The regulation by a TF Ff ∈ F of a complex Ss is measured as
R(Ss, Ff ) =
∑
{p:p∈Ss,(p,Ff )∈E}
ρ(p, Ff )
|{p : p ∈ Ss, (p, Ff ) ∈ E}|
, |{p : p ∈ Ss, (p, Ff ) ∈ E}| > 0, (3)
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where {p : p ∈ Ss, (p, Ff ) ∈ E} is the set of proteins of Ss with which Ff physically interacts in the network
H . The regulation by Ff of the complexes T is measured similarly.
Here we consider a TF to regulate a complex only if the TF physically interacts (in the PPI network) with
at least one protein in the complex. From the classical view of transcriptional regulation, this assumption
means that we consider a TF to regulate a set of genes encoding a complex only if the TF physically interacts
with at least one protein from that complex. Although this assumption may be valid for only a subset of
TFs or complexes, we employ it here to simplify our model. Indeed (see Results) we only lose at most 13%
TF-complex pairs due to this assumption.
We then relate changes in regulation by TFs to changes in co-expression of complexes for (Ss, Tt) ∈
M(S, T ) between the two conditions using a log-linear model
∆C(Ss, Tt) =
k∏
f=1
(
∆R(Ss, Tt, Ff )
)γf
, (4)
where ∆R(Ss, Tt, Ff ) = |R(Ss, Ff )−R(Tt, Ff )| is the differential regulation of the complex-pair (Ss, Tt) by
Ff , and γf is the influence coefficient of Ff in regulating the change ∆C(Ss, Tt). Log-linear models are
widely used to approximate non-linear systems because they inherit the benefits of linear models yet allow
a restricted non-linear relationship between inputs and outputs [68].
Equation 4 can be written in matrix form after taking the logarithm as
log[∆C(S, T )] = [Γ] · log[∆R(S, T ,F)], (5)
where log[∆C(S, T )] is a |M(S, T )| × 1 matrix of (log) differential co-expression of complexes,
log[∆R(S, T ,F)] is a |M(S, T )|×k matrix of (log) differential regulation by the TFs (here, |M(S, T )| > k),
and [Γ] is a k × 1 matrix of influence coefficients for the TFs. Given this combinatorial regulation model,
our purpose is to compute the influence coefficients γf (1 ≤ f ≤ k) by solving Equation 5, and for this we
employ singular-value decomposition (SVD) arriving at a least-squares solution [69]. The TF displaying the
highest (absolute) coefficient |γ| has the highest overall influence in regulating changes in co-expression of
complexes.
A simplified example to demonstrate our model
Solving the equation can give positive as well as negative γ values. The absolute value |γ| indicates the
magnitude of the influence, while the sign indicates the direction: TFs of the same sign regulating a set
of complexes work cooperatively, while those of opposite signs work counteractively with each other. To
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understand this consider the following simplified example in which two TFs with influences γ1 and γ2
regulate two complexes A and B as per the following set of equations:
0.50 = (5)γ1 · (10)γ2 −−−−A
0.60 = (6)γ1 · (20)γ2 −−−−B,
(6)
which after taking log10 becomes,
−0.301 = γ1 · (0.699) + γ2 · (1)−−−−A
−0.221 = γ1 · (0.778) + γ2 · (1.301)−−−−B.
(7)
Here we see that the second TF performs at least twice the regulation than the first TF on the two complexes
(5 and 6 vs 10 and 20), the regulation by the second TF is doubled (from 10 to 20) as against a smaller
increase for the first TF (from 5 to 6) between A and B, and yet A and B show roughly the same change
in co-expression (0.50 vs 0.60). This intuitively means that the first TF has a greater influence than the
second TF, and that counteracts the second TF to maintain the co-expression of complexes similar. Indeed
upon solving the equations we get γ1 = −1.293 and γ2 = 0.603, which is interpreted as the first TF being
about twice as influential as the second, with the two TFs working counteractively in regulating A and B.
It is easy to realize a similar example for the cooperative action of TFs.
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Figures
Figure 1 - Changes in complex co-expression and its transcriptional regulation in pancreatic tumour
The complex CHUK-ECR1-IKBKB-IKBKG showed considerable change in its co-expression between normal
and pancreatic tumour conditions. Its regulation by the NFKB family of TFs also exhibited similar changes.
Both the complex and the TF family have been implicated in pancreatic tumours [15, 16].
Figure 2 - Co-expression-wise distribution of PPIs in normal-PDAC and BRCA1-BRCA2 tumours
PPIs from both normal vs PDAC and BRCA1 vs BRCA2 conditions showed significant differences in their
distributions of co-expression values.
Figure 3 - Co-expression-wise distribution of complexes in normal-PDAC and BRCA1-BRCA2 tumours
Complexes from both normal vs PDAC and BRCA1 vs BRCA2 conditions showed significant differences
in their co-expression distributions. Note: a complex with negative co-expression for a condition possibly
means that the complex does not exist under that condition.
Figure 4 - Comparison of co-expression of complexes in normal-PDAC and BRCA1-BRCA2 tumours
Complexes from the two conditions were matched using tJ = 0.67 and δ = 0.10 (see Methods) and differences
between the maximum, average and minimum co-expression values were computed.
The co-expression values are Fisher-transformed. A complex with negative co-expression for a condition
possibly means non-existance of the complex under that condition.
Figure 5 - Examples of dysfunctional complexes in pancreatic and breast tumours
Complexes showing changes in co-expression for (a) normal vs PDAC, and (b) BRCA1 vs BRCA2 tumours.
Figure 6 - Fraction of known cancer genes constituting complexes
• Total COSMIC genes: 118 (present in the PPI network).
• 66.1% of known cancer genes in PDAC were covered in complexes (#256) showing ∆C ≥ 0.10 between
normal to PDAC tumour.
• 53.4% of cancer genes in breast cancer were covered in complexes (#277) showing ∆ ≥ 0.10 between
BRCA1 tumours and BRCA2 tumours.
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Figure 7 – Differential PPI network constructed for normal vs PDAC
(a) Largest component of the network composed of 519 interactions among 558 proteins, out of which 439
(or 84.5%) interactions showed a decrease in co-expression from normal to PDAC (red interactions indicate
increase from normal to PDAC while green indicate decrease); (b) several genes are silenced by ubiquitination
and sumoylation in PDAC; (c) several known drug targets are centered around interactions showing increase
in co-expression.
Figure 8 - Workflow of our approach
A log-linear model (lower portion of the workflow) is devised to relate changes in the co-expression of
complexes with changes in their transcriptional regulation by TFs.
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Tables
Table 1 - Complexes generated under pancreatic (normal-PDAC) and breast (BRCA1-BRCA2) condi-
tions
The matched complexesM are generated by matching complexes between conditions using tJ = 0.67(= 2/3)
and δ = 0.10 (see Methods).
Pancreatic Breast
Complexes Complexes
Condition # |M| Avg size Condition # |M| Avg size
Normal 582 BRCA1 547
256 8.20 277 7.87
PDAC 581 BRCA2 557
Table 2 - Top enriched terms in KEGG pathways and Biological Process in disrupted complexes in
pancreatic (normal vs PDAC) and breast (BRCA1 vs BRCA2) tumours (using DAVID [32])
Pancreatic Breast
Enrichment Enrichment
Category Annotation Genes (%) p-value Annotation Genes(%) p-value
Cell cycle 4.6 3.5x10−13 Cell cycle 3.2 2.7x10−7
Pathways in cancer 6.2 5.8x10−7 Pathways in cancer 5.8 2.9x10−7
RIG-I-like receptor signalling 2.2 1.1x10−5 Nucleotide excision repair 1.6 1.5x10−5
KEGG Neurotrophin signalling 3.0 1.7x10−5 DNA replication 1.4 6.4x10−5
pathways Nucleotide excision repair 1.7 1.9x10−5 Adipocytokine signalling 1.8 7.5x10−7
Pancreatic cancer 2.1 5.7x10−5 Apoptosis 2.1 1.2x10−4
Adipocytokine signalling 2.0 9.7x10−5 Neurotrophin signaling 2.3 9.5x10−4
Regulation of autophagy 1.3 3.4x10−4 Homologous recombination 1.0 1.6x10−3
Mismatch repair 1.0 5.2x10−4 Insulin signaling 2.2 6.0x10−3
Wnt signalling 2.8 2.2x10−3 Mismatch repair 0.9 2.8x10−3
Cell cycle 17.3 1.6x10−35 Chromosome organization 14.3 1.5x10−43
Biological Chromosome organization 13.0 6.2x10−33 Chromatin organization 12.2 1.3x10−40
Process RNA splicing 9.2 2.5x10−28 Cell cycle 14.5 7.0x10−25
Chromatin modification 8.9 1.0x10−27 Regulation of transcription 31.6 1.1x10−24
∼ 700 genes tested in pancreatic and ∼ 550 genes tested in breast
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Table 3 - Changes in co-expression of complexes in pancreatic (normal-PDAC) and breast (BRCA1-
BRCA2) conditions
(The co-expression values are Fisher-transformed)
• ∆C represents the (absolute) change in co-expression of complexes between conditions, that is, increase
or decrease in co-expression of complexes from normal to PDAC or BRCA1 to BRCA2 tumours.
• M′ – complexes with co-expression for normal > PDAC tumour or BRCA1 > BRCA2 tumour
M′′ – complexes with co-expression for PDAC tumour > normal or BRCA2 > BRCA1 tumour.
Pancreatic Breast
Complex Size of ∆C Size of ∆C
type Subset subset Max Avg subset Max Avg
M′ 159 0.969 0.336 225 0.761 0.281
Our M′′ 96 0.421 0.192 52 0.543 0.197
M′ 138 0.602 0.219 386 0.642 0.178
CORUM M′′ 51 0.512 0.209 55 0.347 0.212
Table 4 - Relationship between changes in co-expression of complexes (∆C) and changes in transcrip-
tional regulation by TFs (
∑
∆R)
All coefficient values are positive, and Spearman coefficients were higher than Pearson, indicating a non-linear
relationship between ∆C and
∑
∆R.
Pancreatic Breast
Complex #Complex-TF #Complex-TF
type pairs Pearson Spearman pairs Pearson Spearman
Our 226 0.273 0.436 241 0.206 0.413
CORUM 71 0.298 0.434 32 0.212 0.393
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Table 5 - Influential TFs identified in pancreatic (normal vs PDAC) and breast (BRCA1 vs BRCA2)
tumours
TFs are ranked based on their overall influence (|γ|) for normal vs PDAC and BRCA1 vs BRCA2 tumours.
The normalized-γ values are obtained by dividing the γ values by the maximum |γ|. The significance (p
value) was computed against 10000 background influence values, each generated from 10000 random shuffles
of gene symbols in the expression dataset. The adjusted p-values for differential expression (DE) analysis –
whether up- (↑) or down- (↓) regulated from normal to PDAC and from BRCA1 to BRCA2 tumours – were
computed using limma [54].
Pancreatic Breast
#Complexes DE #Complexes DE
TF γ Norm-γ regulated p-val (p-val) TF γ Norm-γ regulated p-val (p-val)
STAT5B 2.911 1.000 188 0.001 0.021↓ TBP -5.153 -1.000 199 0.001 NS
RREB1 -2.606 -0.895 190 0.004 NS BACH1 4.221 0.819 199 0.003 NS
BACH1 -1.592 -0.547 188 0.001 5.48E-05↑ POU3F2 -3.902 -0.757 199 0.007 NS
SRF 1.522 0.523 40 0.004 3.06E-05↓ RREB1 2.654 0.515 200 0.002 NS
IRF2 -1.462 -0.502 37 0.014 1.24E-06↓ ATF6 -1.185 -0.230 201 0.002 NS
AHR 1.359 0.467 190 0.003 1.93E-11↑ SRF 1.079 0.209 40 0.007 NS
TBP -0.944 -0.324 188 0.002 0.001↑ STAT5B 1.022 0.198 199 0.007 NS
POU3F2 -0.731 -0.251 188 0.002 6.64E-07↓ SIN3A 0.980 0.190 205 0.007 NS
IRF7 -0.654 -0.225 188 0.002 2.50E-06↑ TCF4 0.601 0.117 40 0.007 NS
HSF1 -0.621 -0.213 190 0.001 NS TAL1 0.599 0.116 14 0.007 NS
YY1 0.619 0.213 195 0.001 3.80E-05↑ CEBPβ -0.537 -0.104 201 0.002 NS
STAT1 0.568 0.195 190 0.005 4.79E-06↑ SOX9 0.447 0.087 204 0.008 NS
TP53 0.543 0.187 190 0.004 6.34E-06↑ GATA3 0.422 0.082 90 0.001 0.012↑
XBP1 -0.549 -0.189 190 0.004 0.002↓ STAT1 0.411 0.080 202 0.001 NS
SOX9 0.504 0.173 193 0.004 2.43E-05↑ STAT5A 0.407 0.079 200 0.004 NS
CEBPβ 0.427 0.147 191 0.005 1.71E-08↑ NFκB1 0.390 0.076 202 0.001 NS
ATF6 -0.419 -0.144 191 0.008 NS IRF2 -0.389 -0.075 42 0.006 NS
STAT5A 0.385 0.132 188 0.001 0.004↑ GATA2 -0.323 -0.063 40 0.001 NS
MSX1 0.366 0.126 188 0.002 0.008↑ FOXO1 0.305 0.059 30 0.001 NS
GATA2 0.328 0.113 40 0.001 9.96E-03↓ ESR1 0.282 0.055 24 0.001 0.008↑
TAL1 0.319 0.110 12 0.003 1.09E-07↓ PPARγ 0.279 0.054 60 0.001 NS
FOXO1 -0.306 -0.105 30 0.003 0.001↑ TP53 0.273 0.053 206 NS NS
ESR1 0.254 0.087 27 0.004 3.43E-04↑ YY1 0.274 0.053 206 0.009 NS
JUNB 0.219 0.075 198 0.004 2.44E-07↑ STAT3 -0.222 -0.043 200 0.004 NS
CEBPα 0.187 0.064 194 0.001 NS MYB -0.213 -0.041 60 0.003 NS
STAT3 0.169 0.058 190 0.004 2.34E-06↑ GATA1 0.204 0.040 40 0.001 NS
SP1 0.159 0.055 10 0.001 0.003↑ FOXA1 0.173 0.034 207 0.001 0.006↑
TCF3 0.155 0.053 40 0.001 NS MSX1 0.170 0.033 199 NS NS
BRCA1 0.146 0.050 200 0.003 0.003↑ HSF2 -0.165 -0.032 201 NS NS
SIN3A 0.138 0.047 193 0.001 2.05E-4↑ FOXO3 0.147 0.029 50 0.009 NS
PPARγ 0.124 0.043 13 0.001 NS PPARα 0.133 0.026 40 NS NS
HSF2 0.120 0.041 191 0.001 0.004↑ FOS 0.121 0.023 44 0.005 NS
MAX 0.113 0.039 80 NS N S SP1 0.098 0.019 18 0.003 NS
NFκB1 0.106 0.036 192 0.002 NS TCF3 -0.096 -0.019 90 0.009 NS
FOS 0.044 0.015 42 0.001 NS CEBPα 0.094 0.018 202 0.009 NS
MYB -0.023 -0.008 40 0.002 NS NFκB2 -0.091 -0.018 202 0.003 NS
NFκB2 0.018 0.006 193 0.002 NS JUN 0.080 0.016 205 0.003 NS
FOXO3 -0.001 0.000 90 0.004 NS AHR 0.076 0.015 200 NS NS
– – – XBP1 0.059 0.011 201 0.002 0.017↑
– – – HSF1 -0.056 -0.011 200 0.001 NS
– – – IRF7 -0.033 -0.006 199 0.009 NS
NS: Not significant at p < 0.05. #Genes tested in each case: ∼ 20700.
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